Betta Pharmaceuticals Co., Ltd. (SHE:300558)
China · Delayed Price · Currency is CNY | Market Cap | 20.58B -0.5% |
| Revenue (ttm) | 3.73B +21.4% |
| Net Income | 441.16M +9.1% |
| EPS | 1.05 +8.4% |
| Shares Out | 420.73M |
| PE Ratio | 46.49 |
| Forward PE | 26.16 |
| Dividend | 0.15 (0.31%) |
| Ex-Dividend Date | Jun 9, 2026 |
| Volume | 19,043,918 |
| Open | 49.31 |
| Previous Close | 48.91 |
| Day's Range | 48.78 - 52.49 |
| 52-Week Range | 40.10 - 79.80 |
| Beta | 0.54 |
| Analysts | Hold |
| Price Target | 43.06 (-15.82%) |
| Earnings Date | Aug 6, 2026 |
About Betta Pharmaceuticals
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China and internationally. The company offers Icotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat first-line treatment of locally advanced or non-small-cell lung cancer (NSCLC); Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of NSCLC; and Bevacizumab, an antibody drug against human vascular endothelial growth factor that is used to treat ... [Read more]
Financial Performance
In 2025, Betta Pharmaceuticals's revenue was 3.61 billion, an increase of 24.81% compared to the previous year's 2.89 billion. Earnings were 305.33 million, a decrease of -24.15%.
Financial StatementsNews
Chinese healthcare, biotech firms flock to Hong Kong for IPOs
Eleven Chinese healthcare and biotechnology companies filed applications to list on the Hong Kong stock exchange in the last two days of September, taking advantage of an ongoing investment boom in th...